UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

The measure, which passed with bipartisan support and minor changes, now heads back to the House. It is just the second ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

But what if you could avoid getting COVID-19 altogether? That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific conference in San ...

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics,” is a game-changer for biopharmaceutical ...

A new combination pill has been given the green light by the National Institute for Health and Care Excellence (Nice) to ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...